NFE2L2 and cancer: In conclusion, our findings demonstrate the upregulation of the NRF2–KYNU axis through multiple cancer types and highlight the relevance of tumoral KYNU as a marker of tumor immunosuppression and as a prognostic marker for poorer overall survival.